Use of compounds as inhibitors for Helicobacter flavodoxin

Details Use of compounds as inhibitors for Helicobacter flavodoxin Use of compounds as inhibitors for Helicobacter flavodoxin

2008-02-20

2011-12-20

Andres, Janet (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S170000, C549S023000, C549S399000, C549S404000, C549S405000

Reexamination Certificate

active

08080664

ABSTRACT:
Use of the general formula compound (I), or any salt thereof, for preparation of a pharmaceutical compound for the treatment of infections illnesses, in particular for the treatment ofHelicobacter. Y is NO2, COOH or SO3H; Z is O, N or S; X1and X2are halogen atoms which may be the same or different; and m and n take values from 0 to 3 and may be equal or different.

REFERENCES:
patent: 3394191 (1968-07-01), Oftedahl
patent: 3629465 (1971-12-01), Manowitz et al.
patent: 3985761 (1976-10-01), Somasekhara et al.
patent: 5763470 (1998-06-01), Tang et al.
patent: 6749645 (2004-06-01), Pasquier et al.
patent: 2004/0167189 (2004-08-01), Bulavin et al.
patent: 2005/0187268 (2005-08-01), Von Rechenberg et al.
patent: 2005/0282818 (2005-12-01), Ramesh et al.
patent: 2006/0247284 (2006-11-01), Caccuri et al.
patent: WO 8803147 (1988-05-01), None
patent: WO 9640110 (1996-12-01), None
patent: WO 9723626 (1997-07-01), None
patent: WO 0035856 (2000-06-01), None
patent: WO2005082341 (2005-09-01), None
Definition for “Infectious Disease” [retrieved May 15, 2011]. Retrieved from the Internet: http://www.merriam-webster.com/medical/infectious+disease?show=0&t=1305401385.
Cremades et al.: ‘Discovery of Specific Flavodoxin Inhibitors as Potential Therapeutic Agents againstHelicobacter pyloriInfection’, ACS Chemical Biology vol. 4, No. 1, pp. 928-938, (Sep. 2, 2009).
Freigang et al.: ‘Crystal structure of oxidized flavodoxin, an essential protein inHelicobacter pylori’, Protein Science, 2002, 11, pp. 253-261, (2002).
Cobalt:—Cobalt RID (seqs), 3 pages and Phylo Tree View for 39 Sequences: Cobalt RID 2UPCRUVR211.
Bem M. et al.: ‘Synthesis of 4-(4′-formylaryloxy)-7-nitrobenzofurazan derivatives from 4-chloro-7-nitrobenzofurazan and some formylphenols in the presence of crown ethers’ Revue Roumaine of Chimie vol. 48, No. 5, pp. 387-392, 2003.
Belton J.G.: ‘A novel N-S oxygen migration in 2,1,3-benzoxadiazole systems’ Proceedings of the Royal Irish Academy. Section B: Biological, Geological and Chemical Science vol. 74, No. 14, pp. 185-192, Aug. 7, 1974.
Beteringhe A. et al.: ‘QSPR study for the hydrophobicity of 4-aryloxy-7-nitrobenzofurazan and 2-aryloxy-(alfa-acetyl)-phenoxathiin derivatives’ Internet Electronic Journal of Molecular Design vol. 5, 2006, pp. 237-246.
Whitehouse M.W. et al.: ‘4-nitrobenzofurazans and 4-nitrobenzofuroxans: a new class of thiol-neutralising agents and potent inhibitors of nucleic acid synthesis in leucocytes’ Biochemical Pharmacology vol. 17, No. 1, 1968, pp. 158-161.
Ghosh P.B. et al.: ‘Potential antileukemic and immunosuppressive drugs. Preparation and in vitro pharmacological activity of some benzo-2,1,3-oxadiazoles (benzofurazans) and their N-oxides (benzofuroxans)’ J. Med. Chem. vol. 11, No. 2, 1968, pp. 305-311.

Affiliated with

Also associated with

Rating

Use of compounds as inhibitors for Helicobacter flavodoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of compounds as inhibitors for Helicobacter flavodoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of compounds as inhibitors for Helicobacter flavodoxin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4311161